We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Misonix Sells Sonablate 500 Console and Sonatherm 600 to US HIFU

By HospiMedica International staff writers
Posted on 07 Jun 2010
Misonix Inc. More...
(MSON; Farmingdale, NY, USA), a leading developer, manufacturer, and marketer of ultrasonic surgical devices, has agreed to sell its "Focus Surgery” related assets plus its European distribution rights to US HIFU LLC (Charlotte, N.C., USA), a privately held healthcare company focused on treating primary and recurrent prostate cancer using HIFU, for US$5.8 million.

The transaction entitles US HIFU with rights to acquire Sonatherm 600, a laparoscopic HIFU system used in the ablation of certain soft tissues. Furthermore, US HIFU will hold distribution rights for Misonix's SB500 console, with Misonix retaining intellectual property rights to the three HIFU patents, which were acquired from ProRhythm in June 2009.

The agreement allows Misonix to focus on minimizing additional operating costs and in developing its own proprietary medical devices such as the HIFU transducers and lens technology. Misonix's President and CEO, Michael A. McManus, Jr. commented on the deal "Going forward, we will be a dedicated ultrasonic surgical device company developing, manufacturing and selling only devices we own outright."

The acquisition of the Sonatherm 600 is a major step for US HIFU; this being the company's first significant device, which has received the mandatory US Food and Drug Administration (FDA; Atlanta, GA, USA), clearance, for commercialization in the United States. Sonatherm is a high intensity focused ultrasound (HIFU) treatment of soft tissue, developed by Misonix after it acquired worldwide rights for the product from Focus Surgery, Inc. in July 2008.

The addition of Sonablate HIFU (a minimally invasive medical device used for the treatment of prostate cancer) will add momentum to the US HIFU's plans for a Pan European initiative to showcase the enhanced efficacy of Sonablate HIFU. This device, which is authorized and commercially available in more than 30 other countries, is in its final phase of the FDA's clinical trials.

"This transaction brings Sonablate manufacturing, and research and development together again under one roof… allowing for increased efficiency operationally and an expansion of our HIFU product portfolio," said US HIFU's CEO Steve Puckett, Jr.

Related Links:

Misonix Inc.
US HIFU




Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Bipolar Coagulation Generator
Aesculap
ow Frequency Pulse Massager
ET10 L
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.